Eli Lilly's Obesity Pill: Goldman Sachs Analyst on Trial Results and Market Opportunity

Trial Results and Market Reaction

• 💡 Eli Lilly's stock experienced a significant drop despite beating earnings estimates and raising guidance, due to trial data for its oral obesity pill, Cipripon, falling slightly below Wall Street expectations.
• 🎯 The Attain One trial showed 12.7% weight loss, which was just shy of the anticipated mid-teens percentage (around 14-15%) that the market had priced in.
• ⚠️ Analysts view the stock's severe reaction as overdone, believing the drug remains commercially viable and will secure a place in the large and fragmenting obesity market.

Drug Viability and Tolerability

• 🚀 The CEO emphasized the goal of creating a convenient, mass-market oral pill with competitive weight loss, which they believe has been achieved.
• 📈 While the weight loss was slightly below expectations, the company highlighted that the tolerability profile held up, with GI side effects in line with expectations, which is a key metric for doctors.
• ❓ Open questions regarding dropouts are expected to be addressed at the EASD conference, but initial company framing suggests tolerability is not a major concern.

Market Landscape and Opportunity

• ⚖️ The trial results may lead to a repricing of the oral obesity market, potentially benefiting competitors like Novo Nordisk with their oral semaglutide.
• 📊 The US obesity market is substantial, with approximately 100 million obese individuals, and current GLP-1 drug penetration is only 3%, projected to reach 15% by 2030.
• 🌍 The global market is even larger, with around 900 million obese patients and even lower penetration rates, indicating a significant ongoing opportunity for oral obesity medications.